Prelim Prospectus words on Change of ControlTwo interesting things I picked up from the preliminary prospectus:
First, the company is in the midst of doing an analysis of going it alone to sell in the US if they get FDA approval. Since we don't need a US partner to help fund another clinical trial, it may not be necessary to get a US partner at all. Much more profit for us.
Second, the prospectus goes into considerable detail on what happens to Berendt's and Olds' compensation contracts if there is a change of control (successful hostile takeover offer). So someone other than just me thinks this is a strong possibility.